查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1592901

感染疾病药物市场：按药物、给药途径、疾病、分销管道和最终用户分类 - 全球预测 2025-2030

Infectious Disease Therapeutics Market by Drug (Antibiotics, Antifungal Drugs, Antiparasitic Drugs), Route of Administration (Intravenous, Oral, Topical), Disease, Distribution Channel, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，感染疾病治疗市场估值为1,162.1亿美元，预计到2024年将达到1,212.7亿美元，复合年增长率为4.41%，到2030年预计将达到1,572.8亿美元。

感染疾病药物是指为对抗病毒、细菌、真菌和寄生虫等病原体引起的感染疾病而开发的治疗方法和药物。这包括抗病毒药物、抗菌、抗真菌和抗寄生虫药物，以及疫苗和个人化医疗。感染疾病的持续爆发、新出现的感染疾病以及抗药性菌株数量的增加凸显了对这一治疗领域的需求，这需要创新的治疗方法来保护公众健康。应用范围广泛，包括医院、诊所和居家医疗，最终用户包括医疗专业人员和患者。市场的关键成长要素包括感染疾病率上升、大量研发投资以及政府促进先进医疗基础设施的措施。此外，COVID-19 大流行凸显了快速开发疫苗和先进治疗解决方案的必要性，从而创造了积极的资金筹措和研究动力。值得注意的机会在于针对抗生素抗药性感染疾病的创新药物的开发、广谱抗病毒药物以及促进个人化治疗的基因组医学的进步。由于医疗保健服务的改善和感染疾病患者数量的增加，亚太和非洲的开拓市场具有巨大的成长潜力。儘管有这样的前景，该领域仍面临着高昂的研发成本、复杂的监管环境以及病原体突变的不可预测性等挑战，这些都使药物功效变得复杂。为了克服这些挑战，建议公共和私营部门之间加强合作并加快核准流程。对于业务扩张至关重要的创新领域包括基因治疗、mRNA疫苗技术以及利用人工智慧的药物发现方法，有望取得突破性成果。该市场的特点是竞争激烈，大量全球和区域参与者争夺技术优势和市场占有率，需要持续创新和策略联盟。将研究快速转化为实际治疗方法对于有效应对不断变化的感染疾病情况至关重要。

主要市场统计
基准年[2023] 1162.1亿美元
预测年份 [2024] 1212.7亿美元
预测年份 [2030] 1572.8亿美元
复合年增长率（%） 4.41%

市场动态：快速发展的感染疾病治疗市场的关键市场洞察

供需的动态交互作用正在改变感染疾病药物市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 世界各地感染疾病的扩大
    • 政府为减轻感染疾病负担所做的努力和迅速行动
    • 专利到期和学名药进入增加
  • 市场限制因素
    • 感染疾病药物对健康的不良影响
  • 市场机会
    • 感染疾病开发新药投入快速增加
    • 感染疾病免疫治疗的最新进展
  • 市场挑战
    • 感染疾病管理替代治疗方法的可用性

波特五力：驾驭感染疾病药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解感染疾病治疗市场的外部影响

外部宏观环境因素对感染疾病药物市场的表现动态起着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解感染疾病治疗药物市场的竞争状况

感染疾病治疗药物市场的详细市场占有率分析提供了对供应商绩效的全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵感染疾病治疗市场供应商的绩效评估

FPNV 定位矩阵是评估感染疾病药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘感染疾病治疗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，感染疾病药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 感染疾病在世界各地的传播加剧
      • 政府为减轻感染疾病负担所做的努力和迅速行动
      • 专利到期和学名药的增加引入
    • 抑制因素
      • 感染疾病药物造成的健康损害
    • 机会
      • 感染疾病开发新药投入快速增加
      • 感染疾病免疫治疗的最新进展
    • 任务
      • 感染疾病管理替代治疗方法的可用性
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章感染疾病治疗药品市场（依药品）

  • 抗生素
  • 抗真菌药物
  • 抗寄生虫药
  • 抗病毒药物

第七章感染疾病治疗药物市场：依给药途径

  • 静脉
  • 口服
  • 话题

第八章感染疾病治疗药物市场：依疾病分类

  • 肝炎
  • HIV
  • 流感
  • 疟疾
  • 结核

第九章感染疾病治疗药物市场：依通路分类

  • 离线
  • 在线的

第十章感染疾病治疗药物市场：依最终使用者分类

  • 居家照护设施
  • 医院/诊所

第十一章 北美和南美感染疾病治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区感染疾病治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲感染疾病治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Allergan PLC
  • Amgen Inc.
  • Astellas Pharma US, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BioCryst Pharmaceuticals, Inc.
  • Biogen Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Chimerix, Inc.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Mitsubishi Chemical Group Corporation
  • Mylan NV
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Co. Ltd.
Product Code: MRR-F6513A06BE17

The Infectious Disease Therapeutics Market was valued at USD 116.21 billion in 2023, expected to reach USD 121.27 billion in 2024, and is projected to grow at a CAGR of 4.41%, to USD 157.28 billion by 2030.

Infectious Disease Therapeutics refers to treatments and drugs developed to combat infectious diseases caused by pathogens such as viruses, bacteria, fungi, and parasites. The scope of this market is broad, enveloping antiviral, antibacterial, antifungal, and antiparasitic agents, alongside vaccines and personalized medicine. The necessity of this therapeutics segment is underscored by continual outbreaks, emerging infectious diseases, and an increasing prevalence of drug-resistant strains, which require innovative treatments to safeguard public health. Applications extend across hospitals, clinics, and home healthcare settings, with end-users including healthcare providers and patients. Key growth influencers in the market include the rising incidence of infectious diseases, substantial R&D investments, and government initiatives promoting advanced healthcare infrastructure. Furthermore, the COVID-19 pandemic has highlighted the critical need for rapid vaccine development and advanced therapeutic solutions, creating invigorated funding and research momentum. Noteworthy opportunities lie in the development of innovative drugs targeting antibiotic-resistant infections, broad-spectrum antivirals, and advancements in genomic medicine facilitating tailored treatments. Developing markets in Asia-Pacific and Africa present considerable growth potential due to improving healthcare access and rising infectious disease cases. Despite these prospects, the sector faces challenges such as high R&D costs, complex regulatory landscapes, and the unpredictability of pathogen mutation, complicating drug efficacy. To overcome these, robust public-private collaborations and accelerated approval processes are recommended. Innovation areas crucial for business expansion include gene therapy, mRNA vaccine technologies, and AI-driven drug discovery methods, which hold promise for breakthrough results. The market is characterized by intense competition due to a plethora of global and regional players striving for technological superiority and market share, necessitating continuous innovation and strategic alliances. Emphasizing the swift translation of research into actionable therapeutics remains imperative to meet the evolving landscape of infectious diseases effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 116.21 billion
Estimated Year [2024] USD 121.27 billion
Forecast Year [2030] USD 157.28 billion
CAGR (%) 4.41%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Infectious Disease Therapeutics Market

The Infectious Disease Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of infectious disease across the globe
    • Government initiatives and prompt actions to reduce the burden of infectious disease
    • Increasing number of patent expirations and entry of generic drugs
  • Market Restraints
    • Adverse health outcomes of infectious disease drugs
  • Market Opportunities
    • Surging investments for development of new drugs to treat infectious diseases
    • Recent advances in immunotherapies against infectious disease
  • Market Challenges
    • Availability of alternative treatments for infectious disease management

Porter's Five Forces: A Strategic Tool for Navigating the Infectious Disease Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Infectious Disease Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Infectious Disease Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Infectious Disease Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Infectious Disease Therapeutics Market

A detailed market share analysis in the Infectious Disease Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Infectious Disease Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Infectious Disease Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Infectious Disease Therapeutics Market

A strategic analysis of the Infectious Disease Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Infectious Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alexion Pharmaceuticals, Inc., Allergan PLC, Amgen Inc., Astellas Pharma US, Inc., AstraZeneca PLC, Bayer AG, BioCryst Pharmaceuticals, Inc., Biogen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Chimerix, Inc., Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Mitsubishi Chemical Group Corporation, Mylan N.V., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A., and Takeda Pharmaceutical Co. Ltd..

Market Segmentation & Coverage

This research report categorizes the Infectious Disease Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug, market is studied across Antibiotics, Antifungal Drugs, Antiparasitic Drugs, and Antiviral Drugs.
  • Based on Route of Administration, market is studied across Intravenous, Oral, and Topical.
  • Based on Disease, market is studied across Hepatitis, HIV, Influenza, Malaria, and Tuberculosis.
  • Based on Distribution Channel, market is studied across Offline and Online.
  • Based on End-User, market is studied across Homecare Facilities and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of infectious disease across the globe
      • 5.1.1.2. Government initiatives and prompt actions to reduce the burden of infectious disease
      • 5.1.1.3. Increasing number of patent expirations and entry of generic drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse health outcomes of infectious disease drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Surging investments for development of new drugs to treat infectious diseases
      • 5.1.3.2. Recent advances in immunotherapies against infectious disease
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of alternative treatments for infectious disease management
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Infectious Disease Therapeutics Market, by Drug

  • 6.1. Introduction
  • 6.2. Antibiotics
  • 6.3. Antifungal Drugs
  • 6.4. Antiparasitic Drugs
  • 6.5. Antiviral Drugs

7. Infectious Disease Therapeutics Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intravenous
  • 7.3. Oral
  • 7.4. Topical

8. Infectious Disease Therapeutics Market, by Disease

  • 8.1. Introduction
  • 8.2. Hepatitis
  • 8.3. HIV
  • 8.4. Influenza
  • 8.5. Malaria
  • 8.6. Tuberculosis

9. Infectious Disease Therapeutics Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Offline
  • 9.3. Online

10. Infectious Disease Therapeutics Market, by End-User

  • 10.1. Introduction
  • 10.2. Homecare Facilities
  • 10.3. Hospitals & Clinics

11. Americas Infectious Disease Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Infectious Disease Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Infectious Disease Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alexion Pharmaceuticals, Inc.
  • 3. Allergan PLC
  • 4. Amgen Inc.
  • 5. Astellas Pharma US, Inc.
  • 6. AstraZeneca PLC
  • 7. Bayer AG
  • 8. BioCryst Pharmaceuticals, Inc.
  • 9. Biogen Inc.
  • 10. Boehringer Ingelheim GmbH
  • 11. Bristol-Myers Squibb Company
  • 12. Celgene Corporation
  • 13. Chimerix, Inc.
  • 14. Eli Lilly and Company
  • 15. Gilead Sciences, Inc.
  • 16. GlaxoSmithKline PLC
  • 17. Johnson & Johnson Services, Inc.
  • 18. Merck & Co., Inc.
  • 19. Mitsubishi Chemical Group Corporation
  • 20. Mylan N.V.
  • 21. Novartis AG
  • 22. Novo Nordisk A/S
  • 23. Pfizer Inc.
  • 24. Sanofi S.A.
  • 25. Takeda Pharmaceutical Co. Ltd.

LIST OF FIGURES

  • FIGURE 1. INFECTIOUS DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. INFECTIOUS DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. INFECTIOUS DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. INFECTIOUS DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. INFECTIOUS DISEASE THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIPARASITIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HIV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY MALARIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOMECARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM INFECTIOUS DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. INFECTIOUS DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 238. INFECTIOUS DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023